NCT01990196 is a Phase 2 clinical trial of degarelix in Prostate Cancer, sponsored by Jonsson Comprehensive Cancer Center.

Who is sponsoring NCT01990196?

NCT01990196 is sponsored by Jonsson Comprehensive Cancer Center.

What drugs are being tested in NCT01990196?

Interventions in NCT01990196: degarelix, enzalutamide, trametinib, dasatinib.

What condition does NCT01990196 study?

NCT01990196 studies Prostate Cancer.

Is NCT01990196 still recruiting?

NCT01990196 is currently active, enrolled. Last updated 17 August 2025.

Last reviewed 2025-08-17 · How we verify

NCT01990196

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer

Active, enrolled Phase 2 Last updated 17 August 2025

What this trial tests

Phase 2 trial testing degarelix in Prostate Cancer in 45 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

23 September 2014

Primary endpoint
23 September 2024

30 September 2026

Quick facts

Lead sponsor	Jonsson Comprehensive Cancer Center
Phase	Phase 2
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	45
Start date	23 September 2014
Primary completion	23 September 2024
Estimated completion	30 September 2026
Sites	1 location across United States

Drugs / interventions tested

degarelix (degarelix) — full drug profile →
enzalutamide (enzalutamide) — full drug profile →
trametinib (trametinib) — full drug profile →
dasatinib (dasatinib) — full drug profile →

Conditions studied

Prostate Cancer — all drugs for Prostate Cancer →

Sponsor

Jonsson Comprehensive Cancer Center — full company profile →

Who can join

18 and older, male only, with Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Prostate cancer is the most common cancer in men and the second leading cause of cancer death in men. The purpose of this research study is to compare prostate cancers treated with hormone therapy versus prostate cancers treated with hormone therapy plus drugs that directly target cancer cells.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

The PI3K-AKT-mTOR Pathway and Prostate Cancer: At the Crossroads of AR, MAPK, and WNT Signaling.
Shorning BY, Dass MS, Smalley MJ, Pearson HB. · · 2020 · cited 437× · PMID 32630372 · DOI 10.3390/ijms21124507
EMT: Present and future in clinical oncology.
Santamaria PG, Moreno-Bueno G, Portillo F, Cano A. · · 2017 · cited 181× · PMID 28590039 · DOI 10.1002/1878-0261.12091
MAPK Reliance via Acquired CDK4/6 Inhibitor Resistance in Cancer.
de Leeuw R, McNair C, Schiewer MJ, Neupane NP, et al · · 2018 · cited 93× · PMID 29739788 · DOI 10.1158/1078-0432.ccr-18-0410
Androgen-targeted therapy-induced epithelial mesenchymal plasticity and neuroendocrine transdifferentiation in prostate cancer: an opportunity for intervention.
Nouri M, Ratther E, Stylianou N, Nelson CC, et al · · 2014 · cited 63× · PMID 25566507 · DOI 10.3389/fonc.2014.00370
The promising role of new molecular biomarkers in prostate cancer: from coding and non-coding genes to artificial intelligence approaches.
Alarcón-Zendejas AP, Scavuzzo A, Jiménez-Ríos MA, Álvarez-Gómez RM, et al · · 2022 · cited 60× · PMID 35422101 · DOI 10.1038/s41391-022-00537-2
Contribution of Epithelial Plasticity to Therapy Resistance.
Santamaría PG, Moreno-Bueno G, Cano A. · · 2019 · cited 47× · PMID 31091749 · DOI 10.3390/jcm8050676
OncoLoop: A Network-Based Precision Cancer Medicine Framework.
Vasciaveo A, Arriaga JM, de Almeida FN, Zou M, et al · · 2023 · cited 38× · PMID 36374194 · DOI 10.1158/2159-8290.cd-22-0342
Role of c-Src in Carcinogenesis and Drug Resistance.
Raji L, Tetteh A, Amin ARMR. · · 2023 · cited 35× · PMID 38201459 · DOI 10.3390/cancers16010032

Verify or expand the search:

Other trials of degarelix

Trials testing the same drug.

NCT05701007 — Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland · completed
NCT02278185 — Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer · Phase 2 · completed
NCT01964170 — A Study to Compare the Effect of ASP3550 With Goserelin in Patients With Prostate Cancer · Phase 3 · completed
NCT01261572 — Study to Find Maintenance Dose for Periodic Administration of ASP3550 · Phase 2 · completed

Other recruiting trials for Prostate Cancer

Currently open trials in the same condition.

NCT06960798 — Characterizing the Genomic Landscape of Prostate Cancer in Native American Populations (NAT-Geno) · recruiting
NCT07237269 — Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer · Phase 2 · recruiting
NCT07234981 — PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer · Phase 2 · recruiting
NCT07027124 — Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Ris · Phase 2 · recruiting
NCT07426094 — PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate · Phase 2, PHASE3 · recruiting

Other Jonsson Comprehensive Cancer Center trials

Trials by the same sponsor.

NCT07229339 — Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer · Phase 2 · not yet recruiting
NCT06448286 — PH Weighted Chemical Exchange Saturation Transfer MRI-Based Surgical Resection to Improve Survival in Patients With Glio · Phase 3 · not yet recruiting
NCT07517211 — A Prospective Study of Physical Function in Adults Who Receive Systemic Therapy for Stage I-III Gastroesophageal Cancer, · not yet recruiting
NCT07191717 — Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Resi · Phase 2 · not yet recruiting
NCT07468903 — Focal Radiation Therapy (HDR-Brachytherapy) for the Treatment of Prostate Cancer · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01990196 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Jonsson Comprehensive Cancer Center
Last refreshed: 17 August 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01990196.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing